Glaukos' Insider Sales: Diversification, Not Distress, Amidst Strong Growth

Related Articles

EQH Insider Sales: Diversification, Not Distress, Amidst Transformative Merger

1 months ago

Life360's Insider Sales: Diversification, Not Distress, Despite Stock Slide

1 months ago

Alignment Healthcare's Insider Sales Signal Diversification, Not Distress, Amidst Medicare Advantage Policy Headwinds

2 months ago

Arista Networks' Insider Sales: Diversification Amidst AI Growth Scrutiny

2 months ago

Category

You may also like

Stock News•2 weeks ago

GKOS Stock Surges 67% Year to Date: What's Driving the Rally?

Glaukos (GKOS) stock surged 67% year to date, driven by iDose TR momentum and the Epioxa launch, which lifted 2026 guidance and expanded its ophthalmology platform.

GKOS

Share

Stock News•3 weeks ago

Insider Sheds Nearly 53,000 Shares of Consumer Health Stock, Valued at Almost $900,000

An insider sold nearly 53,000 shares of a consumer health stock for ~$900,000 at $16.78 per share, liquidating 54% of their direct stake after a 23% 12-month gain.

BLCO

Share

Stock News•1 months ago

Glaukos CFO Alex Thurman Sells $1.6 Million in Stock. What Should Investors Do Now?

Glaukos CFO Alex Thurman sold 10,000 shares for ~$1.6M at $155/share on July 9, representing 19% of his total equity holdings.

GKOS

Share